Results of a phase I trial with Haploidentical <scp>mbIL</scp>‐21 ex vivo expanded <scp>NK</scp> cells for patients with multiply relapsed and refractory <scp>AML</scp> - KIVIRID

Results of a phase I trial with Haploidentical <scp>mbIL</scp>‐21 ex vivo expanded <scp>NK</scp> cells for patients with multiply relapsed and refractory <scp>AML</scp>

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/10.1002/ajh.27281

Keywords:

Abstract:

Source: